VIDEO: Xipere demonstrates durability, safety in real-world setting

BySteven Yeh, MD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

In this Healio Video Perspective from the Retina Society meeting, Steven Yeh, MD, of Stanley M. Truhlsen Eye Institute, discusses Xipere for the treatment of noninfectious uveitis-associated macular edema.

A study investigated nearly 800 eyes of 750 patients treated with Xipere (triamcinolone acetonide injectable suspension, Bausch + Lomb). Notably, more than 40% of patients in the study were diagnosed with glaucoma.

“Patients who received Xipere, a single dose, did not require rescue therapy, with the majority of patients, around 88%, receiving only a single dose of Xipere and only 14% showing an elevation in intraocular pressure,” he said.

Reference:

Singer M. Durability of suprachoroidal injection of triamcinolone acetonide injectable suspension for uveitic macular edema and use of rescue therapy in clinical practice. Presented at: Retina Society meeting; Sept. 11-15, 2024; Lisbon, Portugal.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Yeh reports consulting for Bausch + Lomb and being an investigator in the PEACHTREE trial.

Read more

VIDEO: Xipere demonstrates durability, safety in real-world setting

Reference:

Related Content